BACKGROUND: Polyethylene glycol-3350 without electrolytes (MiraLAX; Schering-Plough Healthcare Products Inc.)+a carbohydrate-electrolyte solution (Gatorade; PepsiCo Inc.)+bisacodyl is frequently used for bowel cleansing, although limited data quantifies its efficacy and safety. No prior studies have assessed this in a community setting or with PM-only dosing, which is still used frequently. AIM: To compare the frequency of excellent/good/fair/poor bowel cleansing with PM-only dosing of MiraLAX-Gatorade-bisacodyl versus 4-liter GoLytely. METHODS: This is a retrospective endoscopic database analysis of 50 years and older average-risk individuals with a normal screening colonoscopy at a community hospital and ambulatory endoscopy center. Data were extracted for the last 4 months when 4-liter GoLytely was the preferred bowel purgative and the first 4 months when 238-g MiraLAX in 64-ounce Gatorade and four 5-mg bisacodyl tablets became the preferred purgative. All patients used PM-only dosing of bowel purgative. RESULTS: A total of 778 subjects [GoLytely (n=395) vs. MiraLAX+Gatorade+bisacodyl (n=383)] were identified. Patients who took the MiraLAX bowel preparation were more likely to achieve an excellent/good bowel cleansing compared with patients taking the GoLytely preparation (93.3% vs. 89.3%, respectively; P=0.048). However, when only American Society of Anesthesiology (ASA) class I patients are studied, there was no difference in frequency of excellent/good bowel cleansing (91.1% vs 93.6%, respectively; P=0.498). No serious adverse events were identified. An excellent/good bowel cleansing was strongly associated with a recommendation for repeat colonoscopy in 10 years compared with patients with a fair cleansing (odds ratio=28.01; 95% confidence interval, 13.96-56.19). CONCLUSIONS: The MiraLAX+Gatorade+bisacodyl combination produces similar rates of excellent/good bowel cleansing as compared with GoLytely in most average-risk individuals undergoing colonoscopy for colorectal screening in a community setting.
BACKGROUND:Polyethylene glycol-3350 without electrolytes (MiraLAX; Schering-Plough Healthcare Products Inc.)+a carbohydrate-electrolyte solution (Gatorade; PepsiCo Inc.)+bisacodyl is frequently used for bowel cleansing, although limited data quantifies its efficacy and safety. No prior studies have assessed this in a community setting or with PM-only dosing, which is still used frequently. AIM: To compare the frequency of excellent/good/fair/poor bowel cleansing with PM-only dosing of MiraLAX-Gatorade-bisacodyl versus 4-liter GoLytely. METHODS: This is a retrospective endoscopic database analysis of 50 years and older average-risk individuals with a normal screening colonoscopy at a community hospital and ambulatory endoscopy center. Data were extracted for the last 4 months when 4-liter GoLytely was the preferred bowel purgative and the first 4 months when 238-g MiraLAX in 64-ounce Gatorade and four 5-mg bisacodyl tablets became the preferred purgative. All patients used PM-only dosing of bowel purgative. RESULTS: A total of 778 subjects [GoLytely (n=395) vs. MiraLAX+Gatorade+bisacodyl (n=383)] were identified. Patients who took the MiraLAX bowel preparation were more likely to achieve an excellent/good bowel cleansing compared with patients taking the GoLytely preparation (93.3% vs. 89.3%, respectively; P=0.048). However, when only American Society of Anesthesiology (ASA) class I patients are studied, there was no difference in frequency of excellent/good bowel cleansing (91.1% vs 93.6%, respectively; P=0.498). No serious adverse events were identified. An excellent/good bowel cleansing was strongly associated with a recommendation for repeat colonoscopy in 10 years compared with patients with a fair cleansing (odds ratio=28.01; 95% confidence interval, 13.96-56.19). CONCLUSIONS: The MiraLAX+Gatorade+bisacodyl combination produces similar rates of excellent/good bowel cleansing as compared with GoLytely in most average-risk individuals undergoing colonoscopy for colorectal screening in a community setting.
Authors: Elizabeth G McFarland; Bernard Levin; David A Lieberman; Perry J Pickhardt; C Daniel Johnson; Seth N Glick; Durado Brooks; Robert A Smith Journal: Radiology Date: 2008-09 Impact factor: 11.105
Authors: Michael Hjelkrem; Joel Stengel; Mark Liu; David P Jones; Stephen A Harrison Journal: Clin Gastroenterol Hepatol Date: 2010-11-27 Impact factor: 11.382
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Kimberly S Andrews; Durado Brooks; John Bond; Chiranjeev Dash; Francis M Giardiello; Seth Glick; David Johnson; C Daniel Johnson; Theodore R Levin; Perry J Pickhardt; Douglas K Rex; Robert A Smith; Alan Thorson; Sidney J Winawer Journal: Gastroenterology Date: 2008-02-08 Impact factor: 22.682
Authors: R W Golub; B A Kerner; W E Wise; D M Meesig; R F Hartmann; K S Khanduja; P S Aguilar Journal: Dis Colon Rectum Date: 1995-06 Impact factor: 4.585
Authors: Phillip Gu; Daniel Lew; Sun Jung Oh; Aarshi Vipani; Jeffrey Ko; Kevin Hsu; Ebrahim Mirakhor; Varun Pattisapu; Tia Bullen; Garth Fuller; Brennan M R Spiegel; Christopher V Almario Journal: Am J Gastroenterol Date: 2019-02 Impact factor: 10.864
Authors: E Waldmann; D Penz; B Majcher; J Zagata; H Šinkovec; G Heinze; A Dokladanska; A Szymanska; M Trauner; A Ferlitsch; M Ferlitsch Journal: United European Gastroenterol J Date: 2018-11-04 Impact factor: 4.623
Authors: Danielle M Tholey; Corbett E Shelton; Gloria Francis; Archana Anantharaman; Robert A Frankel; Paurush Shah; Amy Coan; Sarah E Hegarty; Benjamin E Leiby; David M Kastenberg Journal: J Clin Gastroenterol Date: 2015-04 Impact factor: 3.062
Authors: Kathryn Anastassopoulos; Francis A Farraye; Tyler Knight; Sam Colman; Mark vB Cleveland; Russell W Pelham Journal: Dig Dis Sci Date: 2016-06-09 Impact factor: 3.199